HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q2 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 132 | -2 | 91.18M | $6.60B | +5 | −6 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | — | — |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | — | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | — | −1 |
| Q2 2024 | 14 | — | 8.14M | $426.06M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passief) | 3.03M | — | $158.64M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passief) | 3.03M | — | $158.64M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.30M | — | $68.16M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.30M | — | $68.16M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Norges Bank ✦ (passief) | 1.22M | — | $63.68M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 478.77K | — | $25.07M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Millennium Management ✦ | 423.19K | — | $22.16M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 423.19K | — | $22.16M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 397.78K | — | $20.83M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 377.58K | — | $19.77M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 347.70K | — | $18.21M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 303.28K | — | $15.88M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Arrowstreet Capital ✦ | 102.75K | — | $5.38M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 48.99K | — | $2.56M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 47.77K | — | $2.50M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Bridgewater Associates ✦ | 33.22K | — | $1.74M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 28.38K | — | $1.49M | 0.0% | n/c | 1 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 8 houders, 32.79M aandelen, $43.93M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 9.60K aand · $1.03M
Officer, Director · 3.20K aand · $344,848
Officer, Director · 7.20K aand · $765,778
Officer, Director · 5.70K aand · $587,882
Officer, Director · 9.40K aand · $985,816
Officer, Director · 4.90K aand · $509,827
Officer, Director · 900 aand · $89,062
Officer, Director · 500 aand · $50,228
Officer, Director · 2.10K aand · $213,709
Officer, Director · 9.00K aand · $922,977
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie